Tonix Pharmaceuticals (TNXP) Expected to Announce Quarterly Earnings on Monday

Tonix Pharmaceuticals (NASDAQ:TNXP - Get Free Report) is projected to issue its quarterly earnings data before the market opens on Monday, April 7th. Analysts expect the company to announce earnings of ($6.23) per share and revenue of $3.35 million for the quarter.

Tonix Pharmaceuticals (NASDAQ:TNXP - Get Free Report) last posted its quarterly earnings data on Tuesday, March 18th. The company reported ($9.77) EPS for the quarter, missing analysts' consensus estimates of ($6.23) by ($3.54). Tonix Pharmaceuticals had a negative net margin of 1,197.86% and a negative return on equity of 163.95%. The business had revenue of $2.58 million during the quarter, compared to analyst estimates of $3.20 million. On average, analysts expect Tonix Pharmaceuticals to post $-1,763 EPS for the current fiscal year and $-542 EPS for the next fiscal year.

Tonix Pharmaceuticals Stock Performance

Shares of TNXP traded up $2.02 during mid-day trading on Tuesday, hitting $19.82. 1,648,278 shares of the company's stock were exchanged, compared to its average volume of 740,491. The firm has a market capitalization of $127.54 million, a P/E ratio of 0.00 and a beta of 1.50. Tonix Pharmaceuticals has a fifty-two week low of $6.76 and a fifty-two week high of $672.00. The business's 50 day moving average is $16.04 and its two-hundred day moving average is $20.32. The company has a current ratio of 3.33, a quick ratio of 2.81 and a debt-to-equity ratio of 0.07.

Remove Ads

Analyst Ratings Changes

Several research analysts have weighed in on TNXP shares. Noble Financial reiterated an "outperform" rating and issued a $70.00 target price on shares of Tonix Pharmaceuticals in a research note on Thursday, March 20th. StockNews.com began coverage on shares of Tonix Pharmaceuticals in a research report on Monday, February 10th. They issued a "sell" rating on the stock.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.